[1]赵楠 许杰 李晓晨 穆标 常宝成.腹部脂肪分布对2型糖尿病患者人体成分 及胰岛功能的影响[J].国际内分泌代谢杂志,2019,39(06):361-367.[doi:10.3760/cma.j.issn.1673-4157.2019.06.001]
　Zhao Nan,Xu Jie,Li Xiaochen,et al.Impacts of abdominal fat distribution on body composition and islet function in type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2019,39(06):361-367.[doi:10.3760/cma.j.issn.1673-4157.2019.06.001]
点击复制

腹部脂肪分布对2型糖尿病患者人体成分 及胰岛功能的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年06期
页码:
361-367
栏目:
论著
出版日期:
2019-11-20

文章信息/Info

Title:
Impacts of abdominal fat distribution on body composition and islet function in type 2 diabetic patients
作者:
赵楠 许杰 李晓晨 穆标 常宝成
国家卫生健康委员会激素与发育重点实验室(天津医科大学),天津市代谢性疾病重点实验室,天津医科大学朱宪彝纪念医院&天津市内分泌研究所 300134
Author(s):
Zhao Nan;  Xu Jie;  Li Xiaochen;  Mu Biao;  Chang Baocheng
NHC Key Laboratory of Hormones and Development(Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Chu-Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin 300134, China
关键词:
2型糖尿病;  非酒精性脂肪性肝病;  腹型肥胖;  人体成分;  胰岛素抵抗
Keywords:
Type 2 diabetes mellitus;  Non-alcoholic fatty liver disease;  Visceral obesity;  Body composition;  Insulin resistance
DOI:
10.3760/cma.j.issn.1673-4157.2019.06.001
摘要:
目的 分析2型糖尿病(T2DM)伴或不伴非酒精性脂肪性肝病(NAFLD),以及伴或不伴腹型肥胖患者的人体成分及胰岛功能的差异,探讨脂肪肝及内脏脂肪对胰岛功能的影响。方法 选取519例T2DM患者,根据有无脂肪肝以及是否合并腹型肥胖分为4组,组1:T2DM+NAFLD伴腹型肥胖组242例,组2:T2DM+NAFLD无腹型肥胖组59例,组3:T2DM无NAFLD伴腹型肥胖组101例,组4:T2DM无NAFLD无腹型肥胖组117例。应用生物电阻抗法进行人体成分分析,包括内脏脂肪面积、骨骼肌含量、矿物质含量等指标,同时测定所有患者的肝肾功能、血脂、口服葡萄糖耐量、胰岛功能等生化指标。运用方差分析或非参数检验比较各组人体成分及生化指标,相关性分析采用Spearman秩相关,多因素分析采用二元logistic回归方法。结果(1)组1矿物质含量、蛋白质含量、身体总水分、体重指数大于组4(F=16.202～100.482,P均<0.05); 组1～组4脂肪百分比逐渐下降(T=47.027,P<0.05); 组2骨骼肌含量高于组1(T=2.879,P<0.05)。(2)组1～组4白细胞、C反应蛋白、总蛋白、γ-谷氨酰转肽酶、谷丙转氨酶、谷草转氨酶、肾小球滤过率、血尿酸、甘油三酯、低密度脂蛋白-胆固醇、极低密度脂蛋白-胆固醇呈下降趋势,高密度脂蛋白-胆固醇逐渐上升(F/T=4.036～18.831,P均<0.05)。(3)组1～组4胰岛功能指标:稳态模型评估-胰岛素抵抗指数、稳态模型评估-β细胞功能指数、胰岛素敏感性指数、葡萄糖负荷后胰岛素曲线下面积、C肽曲线下面积呈下降趋势,其中组1与组4间差异有统计学意义(F/T=5.757～13.860,P均<0.05)。(4)校正年龄、性别后,内脏脂肪面积与体重指数、腰臀比、内脏脂肪含量、皮下脂肪含量、基础代谢量、γ-谷氨酰转肽酶、谷丙转氨酶、谷草转氨酶、血尿酸呈正相关(r=0.340～0.916,P均<0.05),与高低密度脂蛋白-胆固醇呈负相关(r=-0.442,P<0.05)。(5)内脏脂肪含量(OR=5.463,95% CI:1.886～4.451,P=0.071)、极低密度脂蛋白-胆固醇(OR=1.224,95% CI:1.180～1.227,P=0.025)为T2DM患者NAFLD的独立危险因素。结论 T2DM合并NAFLD或腹型肥胖患者均会发生胰岛素抵抗及胰岛β细胞功能代偿性增高,且当T2DM患者同时合并NAFLD及腹型肥胖时胰岛素抵抗的程度最明显。增加骨骼肌的含量有利于控制NAFLD患者的腹型肥胖及改善胰岛功能。减少内脏脂肪面积有利于改善代谢指标。
Abstract:
Objective To analyze the differences of body composition and islet function between patients with or without nonalcoholic fatty liver disease(NAFLD), and between patients with or without visceral obesity in type 2 diabetes mellitus(T2DM). The effects of fatty liver and visceral fat on islet function were also investigated.Methods A total of 519 patients with T2DM were divided into 4 groups according to the presence or absence of fatty liver and visceral obesity. Group 1:242 cases of T2DM+NAFLD with visceral obesity, group 2:59 cases of T2DM + NAFLD without visceral obesity, group 3:101 cases of T2DM with visceral obesity but without NAFLD and group 4:117 cases of T2DM without NAFLD and visceral obesity. Bioelectrical impedance method was used to analyze human body composition, including visceral fat area, skeletal muscle content, mineral content and other indicators. At the same time, biochemical indicators such as liver and kidney function, blood lipid, oral glucose tolerance and islet function were measured in all patients. Variance analysis or nonparametric test was used to compare the difference of body composition and biochemical indexes between groups. Spearman rank correlation was used for correlation analysis, and binary logistic regression was used for multivariate analysis.Results(1)The mineral content, protein content, total body water, body mass index in group 1 were higher than those in group 4(F=16.202-100.482, all P<0.05); the percentage of fat was decreased gradually from group 1 to group 4(T=47.027, P<0.05); the skeletal muscle content in group 2 was higher than that in group 1(T=2.879, P<0.05).(2)The white blood cell, C-reactive protein, total protein, albumin, gamma glutamyl transferase, alanine aminotransferase, aspertate aminotransferase, estimated glomerular filtration rate, serum uric acid, triglyceride, low-density lipoprotein-cholesterol and very low-density lipoprotein-cholesterol showed a downward trend, and the level of high density lipoprotein-cholesterol was increased gradually(F/T=4.036-18.831, all P<0.05)from group 1 to group 4.(3)Among the four groups, homeostatic model assessment of insulin resistance, homeostasis model assessment of β cell function, insulin sensitivity index, area under curve of insulin and area under curve of C-peptide showed a downward trend from group 1 to group 4, with significant difference between group 1 and group 4(F/T=5.757-13.860, all P<0.05).(4)After adjusting for age and sex, the visceral fat area was positively correlated with body mass index, waist to hip ratio, visceral fat content, subcutaneous fat content, basal metabolic volume, gamma glutamyl transferase, alanine aminotransferase, aspertate aminotransferase and serum uric acid(r=0.340-0.916, all P<0.05), and negatively correlated with high density lipoprotein-cholesterol(r=-0.442, P<0.05).(5)Visceral fat content(OR=5.463,95% CI:1.886-4.451, P=0.071)and low-density lipoprotein-cholesterol(OR=1.224, 95% CI:1.180-1.227, P=0.025)were independent risk factors for NAFLD in patients with T2DM.Conclusions Both T2DM patients with NAFLD or visceral obesity have insulin resistance and compensatory increase of insulin secretion. The most serious insulin resistance is found in T2DM patients with NAFLD and visceral obesity simultaneously. Increasing skeletal muscle content is beneficial to control visceral obesity and improve islet function in patients with NAFLD. Reducing visceral fat area is beneficial to improve metabolic indicators.

参考文献/References:

[1] Sima A,Timar R,Vlad A,et al.Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients[J].Wien Klin Wochenschr,2014,126(11-12):335-340.DOI:10.1007/s00508-014-0530-8.
[2] Brunt EM.Pathology of nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol,2010,7(4):195-203.DOI:10.1038/nrgastro.2010.21.
[3] Lafargue AL,Cabrales LB,Larramendi RM. Bioelectrical parameters of the whole human body obtained through bioelectrical impedance analysis[J].Bioelectromagnetics,2002,23(6):450-454.DOI:10.1002/bem.10034.
[4] Pietiläinen KH,Kaye S,Karmi A,et al. Agreement of bioelectrical impedance with dual-energy X-ray absorptiometry and MRI to estimate changes in body fat, skeletal muscle and visceral fat during a 12-month weight loss intervention[J].Br J Nutr,2013,109(10):1910-1916.DOI:10.1017/S0007114512003698.
[5] Fan JG,Jia JD,Li YM,et al.Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010:(published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166)[J].J Dig Dis,2011,12(1):38-44.DOI:10.1111/j.1751-2980.2010.00476.x.
[6] 刘德丰,陆强,丁伟利,等.男性腹型肥胖患者内脏脂肪面积与胰岛素抵抗的相关性分析[J]. 中国综合临床, 2014,(7):724-726. DOI:10.3760/cma.j.issn.1008-6315.2014.07.019.
[7] Petta S,Amato MC,Di Marco V,et al.Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2012,35(2):238-247.DOI:10.1111/j.1365-2036.2011.04929.x.
[8] Kruger R,Shultz SP,McNaughton SA,et al.Predictors and risks of body fat profiles in young New Zealand European, Māori and Pacific women: study protocol for the women's EXPLORE study[J].Springerplus,2015,4:128.DOI:10.1186/s40064-015-0916-8.
[9] Subramanian V,Johnston RD,Kaye P,et al.Regional anthropometric measures associated with the severity of liver injury in patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2013,37(4):455-463.DOI:10.1111/apt.12198.
[10] Utzschneider KM,Kahn SE.Review:the role of insulin resistance in nonalcoholic fatty liver disease[J].J Clin Endocrinol Metab,2006,91(12):4753-4761.DOI:10.1210/jc.2006-0587.
[11] Lim S,Oh TJ,Koh KK.Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders[J].Int J Cardiol,2015,201:408-414.DOI:10.1016/j.ijcard.2015.08.107.
[12] Bacchi E,Negri C,Targher G,et al.Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease(the RAED2 Randomized Trial)[J].Hepatology,2013,58(4):1287-195. DOI:10.1002/hep.26393.
[13] 谭擎缨, 姚佳琦,王秀景,等.腹腔内脏脂肪面积与2型糖尿病及血清胰岛素的相关研究[J]. 东南国防医药, 2015,(1): 12-15.DOI:10.3969/j.issn.1672-271X.2015.01.004.
[14] 陈蕾,贾伟平,项坤三,等.肥胖者胰岛素抵抗与总体脂、局部体脂关系的研究[J].中华内分泌代谢杂志,2001,17(5):276-279.DOI:10.3760/j.issn:1000-6699.2001.05.005.
[15] Abate N,Garg A,Peshock RM,et al. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM[J].Diabetes,1996,45(12):1684-1693.DOI:10.2337/diab.45.12.1684.
[16] Choe EY,Lee YH,Choi YJ,et al.Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes[J].J Gastroenterol Hepatol,2018,33(5):1082-1091.DOI:10.1111/jgh.14011.
[17] Klein S,Fontana L,Young VL,et al.Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease[J].N Engl J Med,2004,350(25):2549-2557.DOI:10.1056/NEJMoa033179.
[18] Thörne A,Lönnqvist F,Apelman J,et al.A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding[J].Int J Obes Relat Metab Disord,2002,26(2):193-199.DOI:10.1038/sj.ijo.0801871.
[19] Mantatzis M,Milousis T,Katergari S,et al. Abdominal adipose tissue distribution on MRI and diabetes[J].Acad Radiol,2014,21(5):667-674.DOI:10.1016/j.acra.2014.01.009.
[20] Müller MJ,Lagerpusch M,Enderle J,et al.Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome[J].Obes Rev,2012,13(Suppl 2):6-13.DOI:10.1111/j.1467-789X.2012.01033.x.
[21] Lee J,Lee JY,Lee JH,et al.Visceral fat obesity is highly associated with primary gout in a metabolically obese but normal weighted population: a case control study[J].Arthritis Res Ther,2015,17:79.DOI:10.1186/s13075-015-0593-6.
[22] Kang SH,Cho KH,Park JW,et al.Association of visceral fat area with chronic kidney disease and metabolic syndrome risk in the general population: analysis using multi-frequency bioimpedance[J].Kidney Blood Press Res,2015,40(3):223-230.DOI:10.1159/000368498.
[23] 葛辉,陈君,孙毅明,等.广州市健康体检人群非酒精性脂肪肝患病情况及相关危险因素分析[J]. 中华医学杂志, 2016, 96(46):3706-3709.DOI:10.3760/cma.j.issn.0376-2491.2016.46.003.
[24] 徐芸,王振豫,李继昌,等.腹内型肥胖与非酒精性脂肪肝的关系[J]. 中华肝脏病杂志,2001,9(2):124.DOI:10.3760/j.issn:1007-3418.2001.02.027.
[25] Byrne CD,Targher G.Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease[J].Arterioscler Thromb Vasc Biol,2014,34(6):1155-1161.DOI:10.1161/ATVBAHA.114.303034.
[26] 任颖,刘伟,陆广华,等.2型糖尿病病人的内脏脂肪性肥胖和胰岛素抵抗[J].中国糖尿病杂志,2003,11(2):84-87.DOI:10.3321/j.issn:1006-6187.2003.02.003.

相似文献/References:

[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
　Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
　Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹涵,曲伸.过氧化物酶体增殖物活化受体与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
　Cao Han,Qu Shen..Peroxisome proliferator-activated receptors and non-alcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2014,(06):404.[doi:10.3760/cma.j.issn.1673-4157.2014.06.012]
[4]胡雅琴,包玉倩.维生素D对非酒精性脂肪性肝病的保护作用[J].国际内分泌代谢杂志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
　Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[5]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
　Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[6]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
　Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(06):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[7]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
　Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(06):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[8]聂秀玲,李明珍,孙丽荣.高尿酸血症与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2016,36(02):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
　Nie Xiuling,Li Mingzhen,Sun Lirong..Hyperuricemia and non-alcoholic fatty liver[J].International Journal of Endocrinology and Metabolism,2016,36(06):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
[9]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性 血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
　Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(06):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[10]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白 与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
　Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(06):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[11]李霞 雷涛.铁过载与代谢性疾病的关系[J].国际内分泌代谢杂志,2018,38(01):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
　Li Xia*,Lei Tao..Relationship between iron overload and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(06):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
[12]韩亮 吴凡 陈广.胎球蛋白在非酒精性脂肪性肝病和2型糖尿病中的作用[J].国际内分泌代谢杂志,2018,38(06):419.[doi:10.3760/cma.j.issn.1673-4157.2018.06.015]
　Han Liang*,Wu Fan,Chen Guang.Roles of fetuins in non-alcoholic fatty liver disease and type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(06):419.[doi:10.3760/cma.j.issn.1673-4157.2018.06.015]
[13]吕枭锐 龚凤英.Hepassocin:一种新型的肝细胞因子[J].国际内分泌代谢杂志,2019,39(05):332.[doi:10.3760/cma.j.issn.1673-4157.2019.05.011]
　Lyu Xiaorui,Gong Fengying.Hepassocin: a novel hepatokine[J].International Journal of Endocrinology and Metabolism,2019,39(06):332.[doi:10.3760/cma.j.issn.1673-4157.2019.05.011]
[14]扈若凡 徐少勇 沈涵 景策 贾爱华 鱼馨文 邢影 梁声茹 明洁 姬秋和.非酒精性脂肪性肝病人群细胞角蛋白18 水平与2型糖尿病发病风险[J].国际内分泌代谢杂志,2020,40(04):228.[doi:10.3760/cma.j.issn.1673-4157.2020.04.003]
　Hu Ruofan,Xu Shaoyong,Shen Han,et al.Cytokeratin-18 level and the risk of type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2020,40(06):228.[doi:10.3760/cma.j.issn.1673-4157.2020.04.003]
[15]沈友辉,杜斌.PAI-1引起2型糖尿病合并NAFLD小鼠肝脏炎性反应和纤维化的机制研究[J].国际内分泌代谢杂志,2021,41(02):110.[doi:10.3760/cma.j.cn121383-20200414-04038]
　Shen Youhui,Du Bin..Research of the effects of PAI-1 on inflammation and fibrosis in type 2 diabetic mice with NAFLD[J].International Journal of Endocrinology and Metabolism,2021,41(06):110.[doi:10.3760/cma.j.cn121383-20200414-04038]
[16]王慧,李忠淑.二甲双胍联合恩替卡韦治疗2型糖尿病合并HBV感染并发NAFLD的疗效分析[J].国际内分泌代谢杂志,2022,42(02):124.[doi:10.3760/cma.j.cn121383-20200711-07031]
　Wang Hui,Li Zhongshu..Therapeutic effect of metformin combined with entecavir on type 2 diabetes mellitus complicated with HBV infection and NAFLD[J].International Journal of Endocrinology and Metabolism,2022,42(06):124.[doi:10.3760/cma.j.cn121383-20200711-07031]

备注/Memo

备注/Memo:
通信作者:常宝成,Email:changbc1970@126.com
Corresponding author: Chang Baocheng, Email:changbc1970@126.com
基金项目:国家重点研发计划(2018YFC131400); 国家自然科学基金(81603461,81774043); 天津医科大学朱宪彝纪念医院科研基金(2015DX05,2017DX08)
Fund program:National Key R&D Programm of China(2018YFC1314000); National Natural Science Foundation of China(81603461, 81774043); Scientific Research Funding of Tianjin Medical University Chu Hsien-I Memorial Hospical(2015DX05,2017DX08)
更新日期/Last Update: 2019-11-20